ACAD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 26.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $2,456,977.59

ACADIA Pharmaceuticals Insider Trading History Chart

ACADIA Pharmaceuticals Share Price & Price History

^$26.55

▲ +0.67 (2.59%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

ACADIA Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/18/2025	James Kihara	Insider	Sell	4,084	$23.69	$96,749.96	25,058
11/18/2025	Mark C. Schneyer	EVP	Sell	10,262	$23.69	$243,106.78	53,338
11/10/2025	James M. Daly	Director	Sell	30,000	$22.37	$671,100.00	4,041
9/15/2025	Mark C. Schneyer	EVP	Sell	3,498	$23.65	$82,727.70	43,447
9/2/2025	Elizabeth A Garofalo	Director	Sell	1,600	$25.98	$41,568.00	25,382
8/18/2025	Mark C. Schneyer	EVP	Sell	22,000	$25.18	$553,960.00	40,130
6/4/2025	Laura Brege	Director	Sell	14,446	$21.78	$314,633.88	15,095
5/16/2025	James Kihara	Insider	Sell	4,000	$22.50	$90,000.00	20,395
5/16/2025	Mark C. Schneyer	EVP	Sell	2,000	$25.00	$50,000.00	62,130
5/2/2025	James Kihara	Insider	Sell	1,327	$14.60	$19,374.20	23,526
5/2/2025	Mark C. Schneyer	EVP	Sell	3,498	$14.60	$51,070.80	62,773
4/8/2025	James Kihara	Insider	Sell	1,028	$14.82	$15,234.96	22,257
4/8/2025	Mark C. Schneyer	EVP	Sell	2,708	$14.82	$40,132.56	59,456
3/26/2025	James Kihara	Insider	Sell	1,095	$17.05	$18,669.75	21,275
3/26/2025	Mark C. Schneyer	EVP	Sell	3,171	$17.05	$54,065.55	56,889
3/5/2025	Elizabeth A Garofalo	Director	Sell	4,919	$18.23	$89,673.37	17,595
2/24/2025	James Kihara	Insider	Sell	475	$19.96	$9,481.00	20,228
2/24/2025	Mark C. Schneyer	CFO	Sell	773	$19.96	$15,429.08	53,882
11/19/2024	Brendan Teehan	COO	Sell	10,329	$16.81	$173,630.49	62,105
11/19/2024	James Kihara	Insider	Sell	4,073	$16.81	$68,467.13	19,863
11/19/2024	Mark C. Schneyer	CFO	Sell	10,259	$16.81	$172,453.79	53,302
8/19/2024	Brendan Teehan	COO	Sell	9,534	$15.28	$145,679.52	52,177
8/19/2024	Mark C. Schneyer	CFO	Sell	9,733	$15.28	$148,720.24	43,735
8/19/2024	Stephen R. Davis	CEO	Sell	31,747	$15.28	$485,094.16	186,555
6/10/2024	Mark C. Schneyer	CFO	Sell	975	$14.79	$14,420.25	34,564
5/2/2024	Brendan Teehan	COO	Sell	3,477	$16.94	$58,900.38	42,133
5/2/2024	James Kihara	Insider	Sell	1,326	$16.94	$22,462.44	14,370
5/2/2024	Mark C. Schneyer	CFO	Sell	3,503	$16.94	$59,340.82	32,053
5/2/2024	Stephen R. Davis	CEO	Sell	11,427	$16.94	$193,573.38	155,231
4/8/2024	Brendan Teehan	COO	Sell	2,568	$17.87	$45,890.16	38,796
4/8/2024	James Kihara	Insider	Sell	1,790	$17.87	$31,987.30	13,100
4/8/2024	Mark C. Schneyer	CFO	Sell	2,716	$17.87	$48,534.92	28,742
4/8/2024	Stephen R. Davis	CEO	Sell	26,574	$17.87	$474,877.38	144,267
3/27/2024	Brendan Teehan	COO	Sell	5,140	$17.90	$92,006.00	36,340
3/27/2024	Mark C. Schneyer	CFO	Sell	5,434	$17.90	$97,268.60	26,183
3/27/2024	Stephen R. Davis	CEO	Sell	17,714	$17.90	$317,080.60	118,842
2/26/2024	Brendan Teehan	COO	Sell	624	$24.67	$15,394.08	31,432
2/26/2024	James Kihara	Insider	Sell	474	$24.67	$11,693.58	11,391
2/26/2024	Mark C. Schneyer	CFO	Sell	772	$24.67	$19,045.24	21,067
2/26/2024	Stephen R. Davis	CEO	Sell	5,577	$24.67	$137,584.59	101,890
1/8/2024	Austin D Kim	EVP	Sell	590	$29.96	$17,676.40	46,901
1/8/2024	Brendan Teehan	COO	Sell	731	$29.96	$21,900.76	30,949
1/8/2024	Stephen R. Davis	CEO	Sell	3,732	$29.96	$111,810.72	96,521
12/15/2023	James Kihara	Insider	Sell	2,000	$28.30	$56,600.00	11,025
11/20/2023	Brendan Teehan	COO	Sell	4,960	$22.64	$112,294.40	30,393
11/20/2023	James Kihara	Insider	Sell	1,985	$22.64	$44,940.40	13,025
11/20/2023	Mark C. Schneyer	CFO	Sell	5,108	$22.64	$115,645.12	20,486
10/6/2023	Austin D Kim	EVP	Sell	16,369	$21.96	$359,463.24	45,857
10/6/2023	Stephen R. Davis	CEO	Sell	51,563	$21.96	$1,132,323.48	89,131
9/15/2023	James Kihara	Insider	Sell	2,000	$25.88	$51,760.00	10,778
8/21/2023	Mark C. Schneyer	CFO	Sell	10,000	$29.00	$290,000.00	15,682
7/14/2023	Stephen R. Davis	CEO	Sell	100,000	$30.04	$3,004,000.00	36,695
7/11/2023	Stephen R. Davis	CEO	Sell	16,498	$25.00	$412,450.00	91,799
6/15/2023	James Kihara	Insider	Sell	2,000	$24.15	$48,300.00	9,144
6/12/2023	Laura Brege	Director	Sell	4,500	$24.87	$111,915.00	13,502
6/8/2023	Mark C. Schneyer	CFO	Sell	974	$25.02	$24,369.48	22,824
5/23/2023	Bros. Advisors Lp Baker	Director	Buy	209,053	$25.41	$5,312,036.73	38,811,515
5/17/2023	Brendan Teehan	COO	Sell	14,869	$22.50	$334,552.50	24,356
5/17/2023	James Kihara	Insider	Sell	5,947	$22.50	$133,807.50	11,144
5/17/2023	Mark C. Schneyer	CFO	Sell	15,310	$22.50	$344,475.00	21,905
5/1/2023	Austin D Kim	EVP	Sell	917	$21.18	$19,422.06	25,513
5/1/2023	Brendan Teehan	COO	Sell	548	$21.18	$11,606.64	9,487
5/1/2023	Stephen R. Davis	CEO	Sell	7,806	$21.18	$165,331.08	108,297
4/10/2023	James Kihara	Insider	Sell	523	$18.14	$9,487.22	5,197
4/6/2023	Austin D Kim	EVP	Sell	1,456	$18.16	$26,440.96	23,425
4/6/2023	Brendan Teehan	COO	Sell	1,751	$18.16	$31,798.16	8,468
4/6/2023	James Kihara	Insider	Sell	701	$18.16	$12,730.16	4,231
4/6/2023	Mark C. Schneyer	CFO	Sell	1,916	$18.16	$34,794.56	7,477
4/6/2023	Stephen R. Davis	CEO	Sell	8,582	$18.16	$155,849.12	100,478
2/24/2023	Austin D Kim	EVP	Sell	803	$18.78	$15,080.34	20,108
2/24/2023	Brendan Teehan	COO	Sell	461	$18.78	$8,657.58	5,195
2/24/2023	James Kihara	Insider	Sell	350	$18.78	$6,573.00	2,923
2/24/2023	Mark C. Schneyer	CFO	Sell	577	$18.78	$10,836.06	4,118
2/24/2023	Stephen R. Davis	CEO	Sell	3,851	$18.78	$72,321.78	91,727
1/12/2023	Laura Brege	Director	Sell	12,500	$18.25	$228,125.00
1/9/2023	Austin D Kim	EVP	Sell	589	$17.13	$10,089.57	18,697
1/9/2023	Brendan Teehan	COO	Sell	532	$17.13	$9,113.16	4,549
1/9/2023	Stephen R. Davis	CEO	Sell	3,904	$17.13	$66,875.52	84,633

SEC Filings (Institutional Ownership Changes) for ACADIA Pharmaceuticals (NASDAQ:ACAD)

96.71% of ACADIA Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ACADIA Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/21/2025	CIBC Bancorp USA Inc.	13,267	$0.28M	0.0%	N/A	0.008%
11/19/2025	Danske Bank A S	46,961	$1M	0.0%	N/A	0.028%
11/18/2025	Cim Investment Management Inc.	14,239	$0.30M	0.1%	-51.9%	0.008%
11/17/2025	Jacobs Levy Equity Management Inc.	742,078	$15.84M	0.1%	-2.5%	0.439%
11/17/2025	CANADA LIFE ASSURANCE Co	123,246	$2.63M	0.0%	+1.8%	0.073%
11/17/2025	Woodline Partners LP	151,453	$3.23M	0.0%	-81.9%	0.090%
11/17/2025	Virtus Advisers LLC	42,974	$0.92M	0.6%	+1,283.1%	0.025%
11/17/2025	Verition Fund Management LLC	18,749	$0.40M	0.0%	+63.0%	0.011%
11/17/2025	Scientech Research LLC	37,558	$0.80M	0.3%	N/A	0.022%
11/17/2025	Quarry LP	11,376	$0.24M	0.1%	N/A	0.007%
11/17/2025	Qube Research & Technologies Ltd	596,442	$12.73M	0.0%	-23.9%	0.353%
11/17/2025	Palo Alto Investors LP	2,466,684	$52.64M	9.7%	-3.8%	1.458%
11/17/2025	Mariner LLC	14,643	$0.31M	0.0%	N/A	0.009%
11/17/2025	Millennium Management LLC	1,483,235	$31.65M	0.0%	+2,052.1%	0.877%
11/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	79,741	$1.70M	0.0%	-6.4%	0.047%
11/17/2025	Jain Global LLC	14,051	$0.30M	0.0%	-36.6%	0.008%
11/17/2025	Gotham Asset Management LLC	43,167	$0.92M	0.0%	+145.2%	0.026%
11/17/2025	Fred Alger Management LLC	1,567,035	$33.44M	0.1%	-34.4%	0.926%
11/17/2025	Focus Partners Wealth	19,873	$0.42M	0.0%	N/A	0.012%
11/17/2025	Brevan Howard Capital Management LP	34,992	$0.75M	0.0%	N/A	0.021%
11/17/2025	Bank of America Corp DE	887,848	$18.95M	0.0%	+1.1%	0.525%
11/17/2025	Braidwell LP	2,378,655	$50.76M	1.5%	N/A	1.406%
11/17/2025	Algert Global LLC	400,109	$8.54M	0.1%	+653.6%	0.236%
11/17/2025	Ameriprise Financial Inc.	684,882	$14.62M	0.0%	+7.6%	0.405%
11/14/2025	Creative Planning	36,349	$0.78M	0.0%	+25.0%	0.021%
11/14/2025	Lazard Asset Management LLC	172,821	$3.69M	0.0%	+385.8%	0.102%
11/14/2025	Raymond James Financial Inc.	25,198	$0.54M	0.0%	-15.1%	0.015%
11/14/2025	Virtu Financial LLC	32,815	$0.70M	0.0%	N/A	0.019%
11/14/2025	Amundi	22,455	$0.49M	0.0%	+10.1%	0.013%
11/14/2025	Deep Track Capital LP	105,085	$2.24M	0.1%	N/A	0.062%
11/14/2025	Man Group plc	377,173	$8.05M	0.0%	+31.4%	0.223%
11/14/2025	Horizon Investments LLC	80,972	$1.73M	0.0%	+159.9%	0.048%
11/14/2025	Zurcher Kantonalbank Zurich Cantonalbank	32,800	$0.70M	0.0%	+7.5%	0.019%
11/14/2025	UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC	211,115	$4.51M	0.0%	-38.4%	0.125%
11/14/2025	Two Sigma Investments LP	665,891	$14.21M	0.0%	+37.8%	0.394%
11/14/2025	iSAM Funds UK Ltd	4,349	$93K	0.0%	N/A	0.003%
11/14/2025	Comerica Bank	36,648	$0.78M	0.0%	-16.7%	0.022%
11/14/2025	F m Investments LLC	50,582	$1.08M	0.0%	+4.4%	0.030%
11/13/2025	Marshall Wace LLP	2,358,881	$50.34M	0.1%	+19.8%	1.394%
11/13/2025	GeoWealth Management LLC	42,251	$0.90M	0.0%	N/A	0.025%
11/13/2025	Vise Technologies Inc.	15,367	$0.33M	0.0%	+4.0%	0.009%
11/13/2025	Martingale Asset Management L P	100,328	$2.14M	0.1%	+44.8%	0.059%
11/13/2025	Invesco Ltd.	740,575	$15.80M	0.0%	-13.7%	0.438%
11/13/2025	Arrowstreet Capital Limited Partnership	1,648,864	$35.19M	0.0%	+390.1%	0.975%
11/13/2025	Sei Investments Co.	98,030	$2.09M	0.0%	+7.8%	0.058%
11/13/2025	UBS Group AG	664,846	$14.19M	0.0%	-9.7%	0.393%
11/13/2025	Connor Clark & Lunn Investment Management Ltd.	668,363	$14.26M	0.0%	+4.0%	0.395%
11/13/2025	Capital Fund Management S.A.	77,361	$1.65M	0.0%	-38.2%	0.046%
11/13/2025	BNP Paribas Financial Markets	55,548	$1.19M	0.0%	-27.6%	0.033%
11/13/2025	Franklin Resources Inc.	378,484	$8.08M	0.0%	+143.8%	0.224%
11/13/2025	Magnetar Financial LLC	22,537	$0.48M	0.0%	N/A	0.013%
11/13/2025	Legal & General Group Plc	334,761	$7.14M	0.0%	+1.0%	0.198%
11/13/2025	Vestcor Inc	22,601	$0.48M	0.0%	N/A	0.013%
11/13/2025	Swiss National Bank	227,104	$4.85M	0.0%	+9.7%	0.134%
11/13/2025	Russell Investments Group Ltd.	78,983	$1.69M	0.0%	+65.6%	0.047%
11/13/2025	Schroder Investment Management Group	71,643	$1.53M	0.0%	N/A	0.042%
11/13/2025	Natixis Advisors LLC	64,234	$1.37M	0.0%	-11.0%	0.038%
11/13/2025	First Trust Advisors LP	1,943,152	$41.47M	0.0%	-20.2%	1.149%
11/13/2025	Neo Ivy Capital Management	62,568	$1.34M	0.3%	N/A	0.037%
11/12/2025	Barclays PLC	434,986	$9.28M	0.0%	+1.8%	0.257%
11/12/2025	Dimensional Fund Advisors LP	2,798,134	$59.71M	0.0%	+16.8%	1.654%
11/12/2025	Teachers Retirement System of The State of Kentucky	35,056	$0.75M	0.0%	-10.9%	0.021%
11/12/2025	Victory Capital Management Inc.	241,071	$5.14M	0.0%	+79.7%	0.142%
11/12/2025	Elo Mutual Pension Insurance Co	26,292	$0.56M	0.0%	+76.8%	0.016%
11/12/2025	Fisher Asset Management LLC	638,492	$13.63M	0.0%	+105.8%	0.377%
11/12/2025	Rafferty Asset Management LLC	195,031	$4.16M	0.0%	+55.1%	0.115%
11/12/2025	Quantbot Technologies LP	26,064	$0.56M	0.0%	N/A	0.015%
11/12/2025	Erste Asset Management GmbH	133,700	$2.85M	0.0%	-25.8%	0.079%
11/12/2025	DNB Asset Management AS	13,177	$0.28M	0.0%	+20.7%	0.008%
11/12/2025	Hohimer Wealth Management LLC	101,800	$2.17M	0.3%	-13.6%	0.060%
11/12/2025	Intech Investment Management LLC	48,250	$1.03M	0.0%	-36.0%	0.029%
11/10/2025	TD Asset Management Inc	65,000	$1.39M	0.0%	+44.4%	0.039%
11/10/2025	Ameritas Investment Partners Inc.	10,398	$0.22M	0.0%	-16.9%	0.006%
11/10/2025	Advyzon Investment Management LLC	10,814	$0.23M	0.0%	+13.3%	0.006%
11/10/2025	Citigroup Inc.	1,574,070	$33.59M	0.0%	-5.6%	0.933%
11/10/2025	China Universal Asset Management Co. Ltd.	29,573	$0.63M	0.1%	-12.0%	0.018%
11/10/2025	Jupiter Asset Management Ltd.	476,317	$10.17M	0.1%	-25.2%	0.282%
11/7/2025	CenterBook Partners LP	11,152	$0.24M	0.0%	N/A	0.007%
11/7/2025	GSA Capital Partners LLP	75,902	$1.62M	0.1%	+210.1%	0.045%
11/7/2025	Vanguard Group Inc.	15,179,371	$323.93M	0.0%	-0.6%	8.997%
11/7/2025	JPMorgan Chase & Co.	325,921	$6.96M	0.0%	+4.5%	0.193%
11/7/2025	State of New Jersey Common Pension Fund D	85,821	$1.83M	0.0%	N/A	0.051%
11/7/2025	PNC Financial Services Group Inc.	5,323	$0.11M	0.0%	+11.2%	0.003%
11/7/2025	Shell Asset Management Co.	2,561	$55K	0.0%	-57.4%	0.002%
11/7/2025	GF Fund Management CO. LTD.	3,630	$77K	0.0%	-14.8%	0.002%
11/6/2025	Public Sector Pension Investment Board	486,988	$10.39M	0.0%	+15.3%	0.289%
11/6/2025	Illinois Municipal Retirement Fund	70,683	$1.51M	0.0%	+10.1%	0.042%
11/6/2025	LSV Asset Management	17,200	$0.37M	0.0%	-91.8%	0.010%
11/6/2025	Rhumbline Advisers	391,549	$8.36M	0.0%	+6.7%	0.232%
11/6/2025	Profund Advisors LLC	45,913	$0.98M	0.0%	+48.3%	0.027%
11/6/2025	ProShare Advisors LLC	29,463	$0.63M	0.0%	-13.4%	0.017%
11/6/2025	Oppenheimer Asset Management Inc.	21,843	$0.47M	0.0%	-35.2%	0.013%
11/6/2025	Candriam S.C.A.	537,601	$11.47M	0.1%	N/A	0.319%
11/5/2025	Smartleaf Asset Management LLC	1,712	$36K	0.0%	+107.0%	0.001%
11/5/2025	Alps Advisors Inc.	99,814	$2.13M	0.0%	-10.8%	0.059%
11/5/2025	Envestnet Asset Management Inc.	149,645	$3.19M	0.0%	-8.0%	0.089%
11/4/2025	Allianz Asset Management GmbH	31,873	$0.68M	0.0%	+86.4%	0.019%
11/4/2025	State of Wyoming	8,285	$0.18M	0.0%	N/A	0.005%
11/4/2025	Principal Financial Group Inc.	696,598	$14.87M	0.0%	-1.9%	0.413%
11/4/2025	Thrivent Financial for Lutherans	90,069	$1.92M	0.0%	-1.1%	0.053%

Data available starting January 2016

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $26.55

$25.40

$26.76

50 Day Range

MA: $22.59

$20.06

$26.55

52 Week Range

Now: $26.55

$13.40

$26.76

Volume

1,811,895 shs

Average Volume

1,454,667 shs

Market Capitalization

$4.49 billion

P/E Ratio

17.13

Dividend Yield

N/A

Beta

0.67

Who are the company insiders with the largest holdings of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top insider investors include:
Stephen Davis (CEO)
Mark C Schneyer (EVP)
Brendan Teehan (COO)
Mark C Schneyer (CFO)
Austin D Kim (EVP)
Elizabeth A Garofalo (Director)
James Kihara (Insider)
Laura Brege (Director)
James M Daly (Director)
Learn More about top insider investors at ACADIA Pharmaceuticals.
Who are the major institutional investors of ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals' top institutional shareholders include:
Vanguard Group Inc. — 9.00%
Dimensional Fund Advisors LP — 1.65%
Palo Alto Investors LP — 1.46%
Braidwell LP — 1.41%
Marshall Wace LLP — 1.39%
First Trust Advisors LP — 1.15%
Learn More about top institutional investors of ACADIA Pharmaceuticals stock.
Which institutional investors are selling ACADIA Pharmaceuticals stock?: In the last quarter, ACAD stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Fred Alger Management LLC
Woodline Partners LP
First Trust Advisors LP
Great Lakes Advisors LLC
LSV Asset Management
Qube Research & Technologies Ltd
Jupiter Asset Management Ltd.
During the previous year, company insiders that have sold ACADIA Pharmaceuticals company stock include:
Stephen Davis (CEO)
Mark C Schneyer (EVP)
Brendan Teehan (COO)
Mark C Schneyer (CFO)
Austin D Kim (EVP)
Elizabeth A Garofalo (Director)
Learn More investors selling ACADIA Pharmaceuticals stock.
Which institutional investors are buying ACADIA Pharmaceuticals stock?: During the previous quarter, ACAD stock was purchased by institutional investors including:
Braidwell LP
Millennium Management LLC
Arrowstreet Capital Limited Partnership
Candriam S.C.A.
Dimensional Fund Advisors LP
Marshall Wace LLP
Algert Global LLC
Fisher Asset Management LLC